Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/23ASTELLAS PHARMA : Announces Sale of Certain Agensys Research Facilities to Kite,..
AQ
04/23GILEAD SCIENCES : to Release First Quarter 2018 Financial Results on Tuesday, Ma..
AQ
04/21ASTELLAS PHARMA : sells certain U.S. research facilities to Gilead
AQ
04/20GILEAD SCIENCES : Non-profit KEI sues NIH to block Gilead's anti-CD30 CAR T pate..
AQ
04/19GILEAD SCIENCES : Research Conducted at Gilead Sciences Inc. Has Provided New In..
AQ
04/19GILEAD SCIENCES : New Hepatitis C Virus Data Have Been Reported by Investigators..
AQ
04/19GILEAD SCIENCES : Study Results from Gilead Sciences Broaden Understanding of HI..
AQ
04/19GILEAD SCIENCES : Tmunity tops off series A round
AQ
04/19GILEAD SCIENCES : Astellas Announces Sale of Certain Agensys Research Facilities..
PR
More news
News from SeekingAlpha
04/25GILEAD SCIENCES : Tempting In 2018 
04/25A New Generation Of Novel HIV Small-Molecule Antivirals 
04/24MONTHLY REVIEW OF DIVGRO : March 2018 
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/24JF'S CORE BIOTECH BUYS #12 : Updates And Introducing Our 18th Selection 
Financials ($)
Sales 2018 21 295 M
EBIT 2018 11 197 M
Net income 2018 6 715 M
Debt 2018 17 121 M
Yield 2018 3,11%
P/E ratio 2018 13,91
P/E ratio 2019 13,15
EV / Sales 2018 5,34x
EV / Sales 2019 5,47x
Capitalization 96 498 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 89,0 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Norbert W. Bischofberger CSO, Executive VP-Research & Development
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.31%96 498
VERTEX PHARMACEUTICALS5.89%40 290
REGENERON PHARMACEUTICALS-15.95%34 033
GENMAB20.17%12 599
BEIGENE LTD (ADR)73.75%9 087
BLUEBIRD BIO INC-8.48%8 410